Recap: Redhill Biopharma Q2 Earnings

Shares of Redhill Biopharma RDHL moved higher by 8% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 200.00% over the past year to $0.04, which beat the estimate of ($0.07).

Revenue of $20,899,000 higher by 1237.11% from the same period last year, which missed the estimate of $22,990,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

Redhill Biopharma hasn't issued any revenue guidance for the time being.

Price Action

Company's 52-week high was at $10.17

Company's 52-week low was at $3.26

Price action over last quarter: Up 34.39%

Company Profile

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.